“…Ventricular assist devices (VADs, Table 1 ) were originally introduced in 1990s as bridge to recovery and bridge to cardiac transplantation [ 1 ]. As a consequence of technological advances, left ventricular assist devices (LVADs) are now commonly utilized in patients with chronic left heart failure refractory to maximal medical management as destination therapy [ 2 ]. LVADs have evolved from pulsatile and extracorporeal devices to those implanted within the body to support the circulation with continuous flow provided by an axial (HeartMate II, Abbot, Chicago, IL, USA) or centrifugal (HeartWare HVAD, Medtronic, Dublin, Ireland and HeartMate III, Abbot, Chicago, IL, USA) pump [ 1 ].…”